CytoMed Therapeutics (GDTC) Notes Payables (2021 - 2025)

CytoMed Therapeutics has disclosed Notes Payables across 5 years of filings, most recently posting $31516.6 for Q4 2025.

• In Q4 2025, Notes Payables rose 11.35% year-over-year to $31516.6; the TTM figure through Dec 2025 stood at $31516.6 (up 11.35% YoY), while the FY2025 annual figure was $31765.0, up 15.27% from the prior year.
• Notes Payables came in at $31516.6 for Q4 2025 at CytoMed Therapeutics, up from $28304.4 in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $284211.5 in Q4 2021 to a low of $25128.7 in Q4 2023.
• Average Notes Payables over 5 years is $122078.0, with a median of $31516.6 recorded in 2025.
• Year-over-year, Notes Payables tumbled 89.58% in 2023 and gained 12.64% in 2024.
• Over 5 years, Notes Payables stood at $284211.5 in 2021, then dropped by 15.12% to $241229.0 in 2022, then plunged by 89.58% to $25128.7 in 2023, then climbed by 12.64% to $28304.4 in 2024, then advanced by 11.35% to $31516.6 in 2025.
• Per Business Quant data, the three most recent Notes Payables figures were $31516.6 in Q4 2025, $28304.4 in Q4 2024, and $25128.7 in Q4 2023.